Form 4 for ABBV AbbVie

Accepted 2022-02-22 00:00:00 ET · period of report 2022-02-17 · accession 0001179110-22-001520 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-02-22	2022-02-17	ABBV	Strom Carrie C	SVP, Pres Gbl Allerg Aesth	A - Grant	$0.00	+5,727	48.2K	+13%	$0
D	2022-02-22	2022-02-17	ABBV	Strom Carrie C	SVP, Pres Gbl Allerg Aesth	A - Grant	$0.00	+24.1K	24.1K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, $0.01 par value	2022-02-17	A	A	5,727	$0.00	48,226	D	—	—	(F1) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
2	Derivative	Option(Right to Buy)	2022-02-17	A	A	24,080	$0.00	24,080	D	$144.54 · 2023-02-17 to 2032-02-16	24,080 Common Stock	(F2) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,027 on February 17, 2023, 8,027 on February 17, 2024, and 8,026 on February 17, 2025.